JPMorgan Chase Reduces Stake in AnaptysBio Biotech Firm

The investment bank sold off over 94% of its shares in the clinical-stage immunology company.

Apr. 14, 2026 at 9:23am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavy industrial banking equipment and machinery in muted tones, conceptually representing the complex financial systems and institutional forces behind biotech investments.A major bank's divestment from a clinical-stage biotech firm signals shifting investor sentiment in the immunology space.San Diego Today

JPMorgan Chase & Co. significantly reduced its stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the third quarter, selling off over 232,000 shares and retaining just 14,852 shares, or about 0.05% of the biotech firm's outstanding stock.

Why it matters

This large sell-off by a major institutional investor like JPMorgan Chase could signal a shift in market sentiment around AnaptysBio, which is a clinical-stage company focused on developing antibody-based treatments for immunological and inflammatory disorders.

The details

According to a recent 13F filing, JPMorgan Chase's ownership in AnaptysBio dropped from 5.5% to just 0.05% during the third quarter. The bank sold 232,773 shares, leaving it with a much smaller position of 14,852 shares valued at $455,000.

  • JPMorgan Chase reduced its AnaptysBio stake during the third quarter of 2026.
  • The 13F filing disclosing the sell-off was published on April 14, 2026.

The players

JPMorgan Chase & Co.

A major global investment bank and financial services company.

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on developing antibody-based treatments for immunological and inflammatory disorders.

Got photos? Submit your photos here. ›

The takeaway

This significant sell-off by a major institutional investor like JPMorgan Chase could signal a shift in market sentiment around AnaptysBio, which is still in the clinical stage of developing its pipeline of immunology and inflammation treatments. Investors will be watching closely to see if other large funds follow suit or if AnaptysBio can regain their confidence.